Petros Pharmaceuticals (PTPI) Competitors $0.03 0.00 (-6.00%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTPI vs. RDHL, VRAX, CERO, QLGN, BIVI, ELAB, ENVB, PWUP, CNSP, and LIPOShould you be buying Petros Pharmaceuticals stock or one of its competitors? The main competitors of Petros Pharmaceuticals include Redhill Biopharma (RDHL), Virax Biolabs Group (VRAX), CERo Therapeutics (CERO), Qualigen Therapeutics (QLGN), BioVie (BIVI), PMGC (ELAB), Enveric Biosciences (ENVB), PowerUp Acquisition (PWUP), CNS Pharmaceuticals (CNSP), and Lipella Pharmaceuticals (LIPO). These companies are all part of the "pharmaceutical products" industry. Petros Pharmaceuticals vs. Its Competitors Redhill Biopharma Virax Biolabs Group CERo Therapeutics Qualigen Therapeutics BioVie PMGC Enveric Biosciences PowerUp Acquisition CNS Pharmaceuticals Lipella Pharmaceuticals Redhill Biopharma (NASDAQ:RDHL) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership. Does the media prefer RDHL or PTPI? In the previous week, Redhill Biopharma had 1 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 1 mentions for Redhill Biopharma and 0 mentions for Petros Pharmaceuticals. Redhill Biopharma's average media sentiment score of 0.96 beat Petros Pharmaceuticals' score of 0.00 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Overall Sentiment Redhill Biopharma Positive Petros Pharmaceuticals Neutral Is RDHL or PTPI more profitable? Redhill Biopharma's return on equity of 0.00% beat Petros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A Petros Pharmaceuticals N/A -78.22%-23.50% Which has preferable valuation and earnings, RDHL or PTPI? Petros Pharmaceuticals has lower revenue, but higher earnings than Redhill Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$8.04M0.38-$8.27MN/AN/APetros Pharmaceuticals$5.11M0.17-$8.16M-$52.910.00 Do institutionals and insiders hold more shares of RDHL or PTPI? 7.2% of Redhill Biopharma shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 6.8% of Redhill Biopharma shares are held by insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, RDHL or PTPI? Redhill Biopharma has a beta of 4.18, indicating that its share price is 318% more volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. SummaryRedhill Biopharma beats Petros Pharmaceuticals on 7 of the 10 factors compared between the two stocks. Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PTPI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PTPI vs. The Competition Export to ExcelMetricPetros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$879K$851.82M$5.76B$9.84BDividend YieldN/A4.84%3.95%4.03%P/E Ratio-0.011.1531.3126.60Price / Sales0.1726.88461.57121.29Price / CashN/A19.5637.7659.36Price / Book0.016.7310.026.67Net Income-$8.16M-$4.20M$3.27B$265.59M7 Day PerformanceN/A15.34%3.17%3.42%1 Month PerformanceN/A16.63%4.34%1.09%1 Year PerformanceN/A33.32%44.12%23.84% Petros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PTPIPetros PharmaceuticalsN/A$0.03-6.0%N/A-99.7%$879K$5.11M-0.0120RDHLRedhill BiopharmaN/A$1.48+2.8%N/A-82.1%$3.40M$8.04M0.00210Gap DownVRAXVirax Biolabs Group2.9124 of 5 stars$0.78+1.1%$3.00+283.1%-87.8%$3.36M$10K0.005News CoveragePositive NewsGap DownCEROCERo Therapeutics3.6074 of 5 stars$8.71-1.0%$45.00+416.6%-97.3%$3.34MN/A0.008Earnings ReportQLGNQualigen TherapeuticsN/A$1.98+3.9%N/A-81.9%$3.24M$4.98M0.0050News CoverageBIVIBioVie0.765 of 5 stars$1.78+7.6%N/A-94.4%$3.07MN/A-0.0210ELABPMGC0.7189 of 5 stars$1.98+0.2%N/A-99.6%$2.94M$1.71M0.0018Stock SplitGap DownENVBEnveric Biosciences2.5 of 5 stars$1.15-3.4%$10.00+769.6%-81.2%$2.87MN/A-0.0320News CoveragePositive NewsPWUPPowerUp AcquisitionN/A$0.36-7.8%N/A-95.3%$2.79MN/A0.00N/AGap DownHigh Trading VolumeCNSPCNS Pharmaceuticals1.6308 of 5 stars$6.13-1.0%$300.00+4,794.0%-93.7%$2.76MN/A0.005Gap UpLIPOLipella PharmaceuticalsN/A$0.59-6.2%N/A-82.8%$2.64M$536.36K-0.144 Related Companies and Tools Related Companies Redhill Biopharma Competitors Virax Biolabs Group Competitors CERo Therapeutics Competitors Qualigen Therapeutics Competitors BioVie Competitors PMGC Competitors Enveric Biosciences Competitors PowerUp Acquisition Competitors CNS Pharmaceuticals Competitors Lipella Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PTPI) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access